Ovid Therapeutics
OVID
103 hedge funds and large institutions have $233M invested in Ovid Therapeutics in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 9 closing their positions.
233% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 9
132% more capital invested
Capital invested by funds: $101M → $233M (+$133M)
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
32.21% more ownership
Funds ownership: 47.46% → 79.67% (+32%)
23% more funds holding
Funds holding: 84 → 103 (+19)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less call options, than puts
Call options by funds: $341K | Put options by funds: $411K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$19.2M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.1M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.31M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$6.23M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.99M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.01M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$769K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$698K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWC
101
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $65 | – | – | – |
|
|
SIS
102
Sound Income Strategies
Ft Lauderdale,
Florida
| $13 | – | – | – |
|
103
Barclays
London,
United Kingdom
| $2 | – | – | – |
|
|
104
Acadian Asset Management
Boston,
Massachusetts
| – | -$2.01M | -1,231,698 | Closed |
|
|
AIC
105
AWM Investment Company
New York
| – | -$1.47M | -899,200 | Closed |
|
106
Two Sigma Advisers
New York
| – | -$390K | -239,200 | Closed |
|
|
GCM
107
Graham Capital Management
Rowayton,
Connecticut
| – | -$208K | -127,459 | Closed |
|
|
NMC
108
Nine Masts Capital
Central,
Hong Kong
| – | -$22.8K | -13,960 | Closed |
|
|
TRCT
109
Tower Research Capital (TRC)
New York
| – | -$17.4K | -10,676 | Closed |
|
|
SC
110
Sepio Capital
Salt Lake City,
Utah
| – | -$16.5K | -10,145 | Closed |
|
|
NSIM
111
North Star Investment Management
Chicago,
Illinois
| – | -$1.7K | -1,043 | Closed |
|
|
TCM
112
Tradewinds Capital Management
Bellingham,
Washington
| – | -$163 | -100 | Closed |
|
OVID Hedge Fund Activity: Q1 2026 in Review
103 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2026, worth a combined $233M — up 132% from $101M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new OVID positions and 9 closed out — a net gain of 21 holders — while 33 added to existing stakes and 20 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $19.2M. The largest seller was Point72 Asset Management, cutting an estimated $3.99M.
- 103 institutional investors held Ovid Therapeutics (OVID) as of Q1 2026, up from 84 in Q4 2025.
- Funds reported $233M of Ovid Therapeutics stock for Q1 2026, up 132% quarter-over-quarter.
- 30 funds opened new Ovid Therapeutics positions in Q1 2026 and 9 closed out, a net change of +21 holders.
- The largest Ovid Therapeutics buyer in Q1 2026 was Janus Henderson Group, an estimated $19.2M added.
- The largest Ovid Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $3.99M sold.
Based on aggregated 13F filings for Q1 2026.